Search results for "82"

showing 10 items of 2220 documents

Characteristics and Outcomes of 35 Breast Cancer Patients Infected With COVID-19

2020

Since December 2019, a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly engulfed the world. Cancer patients infected with COVID-19 are considered to carry higher severity of the disease and higher mortality rate than common COVID-19 patients in previous studies. However, due to the poor clinical information on COVID-19 patients with cancer, the evidences that supported this conclusion are insufficient. At present, rather limited reports have analyzed the clinical data of breast cancer patients infected with COVID-19. Therefore, in this retrospective study, we described the clinical characteristics and the outcomes of 35 …

0301 basic medicinemedicine.medical_specialtyCancer ResearchCoronavirus disease 2019 (COVID-19)Diseasemedicine.disease_causelcsh:RC254-282Asymptomatic03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicineMedicineclinical characteristicsCoronavirusOriginal Researchnon-cancerbusiness.industrySARS-CoV-2Mortality rateCancerRetrospective cohort studylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisprognosismedicine.symptombusinessFrontiers in Oncology
researchProduct

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter …

2020

ABSTRACT Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain a major challenge.Tecemotide (L-BLP25) is an antigen-specific cancer vaccine inducing immunity against mucin-1 (MUC1). The LICC trial aimed to improve survival in patients with mCRC after R0/R1 resection of CRLM. LICC was a binational, randomized, double-blind, placebo-controlled, multicenter phase 2 study including patients with R0/R1 resected CRLM without evidence of metastatic disease…

0301 basic medicinemedicine.medical_specialtyLung Neoplasmsmucin-1 (muc1)Colorectal cancermedicine.medical_treatmentImmunologyMedizinPlaceboCancer VaccinesGastroenterologyResectionDouble blind03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGermanyInternal medicinemedicineHumansImmunology and AllergyRC254-282Original ResearchMembrane Glycoproteinsresection of colorectal liver metastasesbusiness.industryLiver NeoplasmsVaccinationNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal neoplasmsRC581-607medicine.diseasedigestive system diseasesVaccination030104 developmental biologyOncologyCurative treatment030220 oncology & carcinogenesistecemotide (l-blp25)TecemotideNeoplasm Recurrence LocalImmunologic diseases. AllergybusinessAdjuvantResearch Articleliver-limited diseaseOncoImmunology
researchProduct

Postoperative intestinal fistula in primary advanced ovarian cancer surgery

2021

Antoni Llueca,1– 3 Anna Serra,1– 3 Maria Teresa Climent,1,2 Karina Maiocchi,2,4 Alvaro Villarin,2,4 Katty Delgado,2,5 Josep Mari-Alexandre,6 Juan Gilabert-Estelles,6,7 Paula Carrasco,3 Blanca Segarra,8 Luis Gomez,2,4 Juan Jose Hidalgo,3 Javier Escrig,3 Manuel Laguna2,4 On behalf of the MUAPOS working group (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery1Department of Gynecology and Obstetrics, University General Hospital of Castellon, Castellón, Spain; 2Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellon, Castellón, Spain; 3Department of Medicine, University Jaume I (UJI), Caste…

0301 basic medicinemedicine.medical_specialtyMultivariate analysiscomplicationsFistulalcsh:RC254-28203 medical and health sciences0302 clinical medicineintestinal fistulaMedicineIn patientintestinal leakageOriginal ResearchAdvanced ovarian canceradvanced ovarian cancer surgerybusiness.industrymedicine.diseaseDebulkinglcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSurgeryBowel obstruction030104 developmental biologyOncologyCancer Management and Research030220 oncology & carcinogenesisConventional PCIPeritoneal Cancer Indexbusiness
researchProduct

Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice

2017

Faecalibacterium prausnitzii is considered as one of the most important bacterial indicators of a healthy gut. We studied the effects of oral F. prausnitzii treatment on high-fat fed mice. Compared to the high-fat control mice, F. prausnitzii-treated mice had lower hepatic fat content, aspartate aminotransferase and alanine aminotransferase, and increased fatty acid oxidation and adiponectin signaling in liver. Hepatic lipidomic analyses revealed decreases in several species of triacylglycerols, phospholipids and cholesteryl esters. Adiponectin expression was increased in the visceral adipose tissue, and the subcutaneous and visceral adipose tissues were more insulin sensitive and less infl…

0301 basic medicinemedicine.medical_specialtyhepatic healthmedicine.medical_treatmentFaecalibacterium prausnitziiAdipose tissueInflammationGut florata3111MicrobiologyMicrobiologyMice03 medical and health sciencesInsulin resistanceInternal medicinemedicineAnimalsIntestinal Mucosaadipose tissue inflammationBeta oxidationEcology Evolution Behavior and SystematicsInflammationgut microbiotaAdiponectinbiologyFaecalibacterium prausnitziiInsulinta1182ta3141Lipid Metabolismbiology.organism_classificationmedicine.diseaseDietary FatsLipids030104 developmental biologyEndocrinologyAdipose TissueLiverOriginal ArticleInsulin Resistancemedicine.symptomThe ISME Journal
researchProduct

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice

2020

Antigen-encoding, lipoplex-formulated RNA (RNA-LPX) enables systemic delivery to lymphoid compartments and selective expression in resident antigen-presenting cells. We report here that the rejection of CT26 tumors, mediated by local radiotherapy (LRT), is further augmented in a CD8+ T cell-dependent manner by an RNA-LPX vaccine that encodes CD4+ T cell-recognized neoantigens (CD4 neoantigen vaccine). Whereas CD8+ T cells induced by LRT alone were primarily directed against the immunodominant gp70 antigen, mice treated with LRT plus the CD4 neoantigen vaccine rejected gp70-negative tumors and were protected from rechallenge with these tumors, indicating a potent poly-antigenic CD8+ T cell r…

0301 basic medicinemedicine.medical_treatmentT cellImmunology03 medical and health sciences0302 clinical medicineAntigenmedicineImmunology and Allergyrna-lpxcd4+ t cellsradiotherapyRC254-282Antitumor activityLiposomeintegumentary systembusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensRNARC581-607Radiation therapy030104 developmental biologymedicine.anatomical_structureOncologyLocal radiotherapy030220 oncology & carcinogenesisCancer researchImmunologic diseases. Allergybusinesscancer vaccinesneoantigensCD8OncoImmunology
researchProduct

Structural Basis of the High Affinity Interaction between the Alphavirus Nonstructural Protein-3 (nsP3) and the SH3 Domain of Amphiphysin-2

2016

We show that a peptide from Chikungunya virus nsP3 protein spanning residues 1728–1744 binds the amphiphysin-2 (BIN1) Src homology-3 (SH3) domain with an unusually high affinity (Kd 24 nM). Our NMR solution complex structure together with isothermal titration calorimetry data on several related viral and cellular peptide ligands reveal that this exceptional affinity originates from interactions between multiple basic residues in the target peptide and the extensive negatively charged binding surface of amphiphysin-2 SH3. Remarkably, these arginines show no fixed conformation in the complex structure, indicating that a transient or fluctuating polyelectrostatic interaction accounts for this …

0301 basic medicinenuclear magnetic resonance (NMR)Amino Acid MotifsStatic ElectricityPeptideTarget peptidePlasma protein bindingViral Nonstructural ProteinsBiologyhost-pathogen interactionBiochemistrySH3 domainsrc Homology Domainsamphiphysin SH3Structure-Activity Relationship03 medical and health sciencesProtein structuredynaminHumansShort linear motifprotein structureNuclear Magnetic Resonance BiomolecularMolecular BiologySrc homology 3 domain (SH3 domain)Adaptor Proteins Signal Transducingchemistry.chemical_classificationTumor Suppressor Proteinsta1182Nuclear ProteinsIsothermal titration calorimetryCell Biologyintrinsically disordered protein030104 developmental biologychemistryBiochemistrynsP3Protein Structure and FoldingAmphiphysinBiophysicsPeptidesChikungunya virusProtein BindingJournal of Biological Chemistry
researchProduct

Structural and functional insights into lysostaphin–substrate interaction

2018

Lysostaphin from Staphylococcus simulans and its family enzymes rapidly acquire prominence as the next generation agents in treatment of S. aureus infections. The specificity of lysostaphin is promoted by its C-terminal cell wall targeting domain selectivity towards pentaglycine bridges in S. aureus cell wall. Scission of these cross-links is carried out by its N-terminal catalytic domain, a zinc-dependent endopeptidase. Understanding the determinants affecting the efficiency of catalysis and strength and specificity of interactions lies at the heart of all lysostaphin family enzyme applications. To this end, we have used NMR, SAXS and molecular dynamics simulations to characterize lysostap…

0301 basic medicinestaphylococcus aureusentsyymitStaphylococcus aureusSH3b domain030106 microbiologyPeptidePeptidoglycanProtein dynamicspeptidoglycanCleavage (embryo)PentaglycineBiochemistry Genetics and Molecular Biology (miscellaneous)Biochemistry03 medical and health scienceschemistry.chemical_compoundHydrolaseMolecular Biosciencessubstrate bindingmolekyylidynamiikkaBinding siteNMR-spektroskopiaMolecular Biologylcsh:QH301-705.5Original Researchchemistry.chemical_classificationantimikrobiset yhdisteetSubstrate InteractionLysostaphinProtein dynamicsta1182030104 developmental biologychemistrylcsh:Biology (General)Substrate bindingprotein dynamicsBiophysicsLysostaphin1182 Biochemistry cell and molecular biologyNMR structurelysostaphinpentaglycinePeptidoglycanFrontiers in Molecular Biosciences
researchProduct

Lack of evidence of mimivirus replication in human PBMCs

2018

The Acanthamoeba polyphaga mimivirus (APMV) was first isolated during a pneumonia outbreak in Bradford, England, and since its discovery many research groups devoted efforts to understand whether this virus could be associated to human diseases, in particular clinical signs and symptoms of pneumonia. In 2013, we observed cytopathic effect in amoebas (rounding and lysis) inoculated with APMV inoculated PBMCs (peripheral blood mononuclear cell) extracts, and at that point we interpreted those results as mimivirus replication in human PBMCs. Based on these results we decided to further investigate APMV replication in human PBMCs, by transmission electron microscopy (TEM) and qPCR. No viral fac…

0301 basic medicinevirukset030106 microbiologyImmunologymimivirusReal-Time Polymerase Chain ReactionVirus ReplicationMicrobiologyPeripheral blood mononuclear cellVirus03 medical and health sciencesMultiplicity of infectionBacterial ProteinsMicroscopy Electron TransmissionacanthamoebaViral factoryHumansCytopathic effectMimivirusbiologyDNA Helicasesta1182biology.organism_classificationVirologyHelicase GeneAcanthamoeba030104 developmental biologyInfectious DiseasesDNA ViralPBMCsLeukocytes MononuclearMimiviridaeMicrobes and Infection
researchProduct

Novel activities of safe-in-human broad-spectrum antiviral agents

2018

According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley feve…

0301 basic medicineviruksetviruses030106 microbiologyAPPROVED DRUGSHEPATITIS-C VIRUSINFLUENZA-A VIRUSBioinformaticsAntiviral AgentsArticle03 medical and health sciencesBroad spectrumVirologyHumansRNA VirusesvirusesCELL-CULTUREPharmacologyZIKA VIRUS-INFECTIONviral diseasesECHOVIRUS 1ta1183DNA VirusesDrug Repositioningta1182MOUSE MODELLIVER-TRANSPLANTATION3. Good healthDrug repositioning030104 developmental biology317 PharmacyVirus DiseasesvirustauditENTRY3111 BiomedicineViral diseaseINHIBITORSAntiviral Research
researchProduct